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Plasmid cDNA encoding the a-chain of either membrane-bound (pcRT.45) or secreted (pcRQ.B3) RT1 A a MHC 
class I Ag were transferred to Lewis (RT1}) rat skeletal muscle by direct injection. Rats were challenged 7 days later 
with an ACl (RT1a) heterotopic heart transplant, and cardiac allograft survival, RT1 Aa-specific antibody levels, and 
frequency of ACI-specific CTL were monitored. Graft rejection was accelerated by >2 days in an Ag-specific and 
dose-dependent manner in pcRT.45-injected rats. The pcRQ.B3-injected rats also rejected grafts more rapidly; 
however, graft rejection was accelerated by only 1 day, and graft infiltrates were less pronounced than in pcRT.45-
injected rats. Injection of pcRT.45 resulted in an increase in ACI-specific CTL precursor frequency 3 days post-
transplant, whereas there was no significant change in rats pretreated with pcRQ.B3 injection. Compared with rats 
injected with a control plasmid encoding firefly luciferase, transfer of pcRT.45 resulted in an increase in RT1 A a -
specific IgG and IgM antibody 3 days after heart transplantation. Transfer of pcRQ.B3 resulted in a similar mean 
increase in RT1 Aa-specific IgG and IgM antibody after transplantation, but the variability from rat to rat was 
greater, with some animals exhibiting strong priming, and others showing little or no priming by gene injection. 
Our results suggest that skeletal muscle can express either membrane-bound or secreted MHC class I Ag after gene 
transfer, but that the membrane-bound form is more immunogenic than the secreted form in the high responder 
Lewis rat. Direct DNA transfer to skeletal muscle provides a rapid and specific approach to studying immunity to 
allogeneic MHC Ag. Journal of Immunology, 1994, 152: 413. 
T he Ir3 to alloantigen depends fundamentally on the form and mode of presentation of the Ag. In trans-plantation, M H C class I Ag may play an important 
role by priming the Ir resulting in accelerated rejection of 
allografts, or by inducing immunologic unresponsiveness 
(1-3). Donor M H C class I A g may be released from an 
allograft in at least two basic forms: 1) as membrane-
associated Ag either on cell surfaces or shed from cell 
surfaces into the extracellular space; or 2) as water-soluble 
secreted Ag. What determines whether these different 
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forms of M H C class I molecules are immunogenic, or have 
tolerogenic properties in vivo is largely unknown. Some ev-
idence suggests that purified water-soluble M H C class I Ag 
may be less immunogenic (4) and less tolerogenic than mem-
brane-bound Ag (5), whereas other data suggest that soluble 
forms of M H C class I (6, 7) and other Ag (8) may have a 
higher potential for inducing immunologic unresponsiveness 
with minimal risk for sensitization. However, the difficulty of 
obtaining purified lipid- and water-soluble M H C molecules 
in large quantities has precluded extensive studies to compare 
their immunologic effects. In addition, it is difficult to mimic 
the activities of cell-derived graft Ag that are secreted, or 
shed continuously, using protein preparations injected daily 
or via continuous infusion methods. In the present study we 
have devised a strategy to study the immunologic effects of 
the different forms of M H C class I Ag in vivo using direct 
gene transfer to skeletal muscle. With this method an allo-
geneic donor strain rat M H C class I Ag (RTlA a ) was ex-
pressed in recipient Lewis rat (RT1A1) myocytes before 
transplantation. This high responder rat strain was chosen be-
cause membrane-bound R T l A a Ag is known to be strongly 
immunogenic in the RT1A 1 haplotype (9). Therefore, if se-
creted R T l A a had different immunologic properties, they 
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could easily be distinguished from those of the strongly im-
munogenic membrane-bound RT1 A a . 
The method of direct gene transfer to skeletal muscle 
has been used to express a variety of gene products in a 
stable manner, including firefly luciferase and j3-galactosi-
dase (10-12). Although rodent myocytes normally ex-
press M H C class I Ag at a low level, they are capable of 
expressing high levels of the Ag after interferon treatment 
(13). Thus, M H C class I Ag expression in myocytes does 
not appear to be limited by such factors as ^-microglob-
ulin insufficiency or lack of peptide-loading capacity that 
might prevent class I assembly after a-chain cDNA trans-
fer. One advantage of using direct cDNA transfer is that 
the cDNA for an allogeneic M H C class I molecule can be 
modified, and the immunologic effect of the alteration may 
readily be determined in vivo. Recently, foreign proteins 
have been expressed by muscle cells after direct gene in-
jection, and typical T and B cell immunologic responses 
are generated (14, 15). Direct transfer of cDNA also per-
mits the expression of a single Ag, avoiding the problem 
of contaminating substances in purified Ag preparations. 
In addition, myocyte syncytia are not mobile, ruling out 
the migration of genetically altered cells to central lym-
phoid tissue. Other gene transfer modalities have been use-
ful in expressing foreign M H C genes in vivo. In "some 
studies tumor cells and hemopoietic tissues have been 
transfected with M H C genes in vitro using DNA-calcium 
phosphate co-precipitation or retroviruses, followed by in 
vivo cell transfer (16, 17). Although these methods are 
useful for transfecting a wider variety of cells and tissues, 
direct gene transfer to skeletal muscle has advantages in-
cluding: 1) it is relatively simple, 2) it does not require in 
vitro transfections before in vivo transfer (although, viral 
vectors can be directly transferred in vivo), 3) it is nonin-
fectious, and 4) it avoids the risk of an Ir to a viral vector 
that could interfere with the interpretation of the Ir against 
the Ag of interest. 
In this study, the cDNA encoding a rat membrane-
bound M H C class I molecule RT1 A a was altered to encode a 
secreted, water-soluble, form of R T l A a . Plasmid constructs 
encoding membrane-bound and secreted R T l A a were ex-
pressed in myocytes after direct cDNA transfer to skeletal 
muscle, allowing us to compare the humoral, CTL, and graft 
rejection responses to membrane-bound vs secreted M H C 
class I Ag in vivo. Despite the ability of transferred cDNA 
encoding either membrane-bound or secreted M H C class I 
Ag to prime an antibody response to R T l A a , our results in-
dicate that membrane-bound M H C class I Ag is more effec-
tive than secreted M H C class I Ag at priming ACI-specific 
CTL and causing accelerated rejection of ACI cardiac al-
lografts. Gene transfer provides a novel method for modify-
ing the allograft response in a transplantation model, and also 
provides a useful technique for studying the Ir to different 
forms of allogeneic M H C class I Ag. 
Materials and Methods 
DNA constructs 
The plasmid containing the R T l A a cDNA, pBS3.3/i (18, 19), was pro-
vided by Dr. Jonathan Howard (Babraham Institute, Cambridge, UK). 
The 1.5-kb EcoRl fragment of pBS3.3/l was isolated and subcloned into 
the CMV expression vector pcDNAl (In Vitrogen, San Diego, CA) to 
create the pcRT.45 expression construct (see Fig. 1A). The pCMVLux 
construct encoding firefly luciferase was obtained from Dr. Jon Wolff 
(Waisman Center, University of Wisconsin, Madison, WI). 
A recombinant construct encoding secreted R T l A a was developed by 
combining a portion of the a3 region of the R T l A a cDNA with the 
transmembrane region of the secreted mouse MHC class Hike molecule, 
Q10b (20) using rPCR methods (21). The upstream primer A (5'-
ACATGGAGCTTGTGGAGACC-3') and downstream primer B (5'-
TCAGTGGAAGGAGGAGGTTCCCATCTCTGGGAAA-3') define a 
150-bp PCR fragment starting just upstream of the Psrl site in the middle 
of the a3 domain of the R T l A a molecule to the junction of the a3 and 
transmembrane domain. A 130-bp PCR fragment of the transmembrane 
domain of Q10b was defined by the upstream primer C (5'-GAACCTC-
CTCCTTCCACTGA-3') and the downstream primer D (5'-GTC-
GACTCTAGATTTCCCACCCGTGTTTCTCCTTCT-3') which con-
tains an Xbal site. Because a portion of primer B is complementary to 
primer C, denaturation and annealing of the two PCR products creates a 
new fusion product that is amplified using the two outside primers A and 
D in a third PCR reaction. After restriction enzyme digestion, this fusion 
product was ligated in the Pstl and Xbal sites of the pcRT.45 plasmid to 
create the final construct encoding secreted R T l A a , pcRQ.B3 (see Fig. 
IB). dsDNA sequencing of the plasmid using Sequenase (U. S. Biochem-
ical, Cleveland, OH) demonstrated the expected sequence in frame. 
Transient transfection 
L-M(TK) cells, American Type Culture Collection, Rockville, MD, were 
transfected with either pcRT.45 or pcRQ.B3 using Lipofectin (GIBCO 
BRL, Gaithersburg, MD). After an overnight incubation with serum-free 
OPTI-MEM (GIBCO BRL) at 37°C, 5% C 0 2 , FCS was added to each 
plate at a final concentration of 10%. Cells and media were harvested on 
day 3 to test for cell-surface expression by flow cytometry and secreted 
R T l A a production by ELISA, respectively. For flow cytometry, cells 
were first reacted with the RTlAa-specific antibody R3/13 (Bioproducts 
for Science, Indianapolis, IN), washed with PBS, then reacted with goat 
anti-rat IgG-FITC (Jackson ImmunoResearch, West Grove, PA). After 
two PBS washes, flow cytometry was performed with a Coulter Profile 
(Coulter Immunology, Hialeah, FL). 
Primary cultured Lewis rat myoblasts were prepared (as described 
in detail elsewhere) (22) and transfected with pcRT.45, pcRQ.B3, or 
pCMVLux using the Lipofectin method. Total R T l A a protein was mea-
sureH by ELISA in both culture supernatants and cell lysates. 
ELISA for RT1Aa 
The ELISA for R T l A a was performed on 96-well half-area EIA plates 
(Costar Corp., Cambridge, MA). Wells were coated with 10 jmg/ml MRC 
OX-18 (specific for a monomorphic determinant of RT1A; Bioproducts 
for Science) overnight at 4°C, blocked for 1 h with 2% BSA in PBS, and 
washed. Purified R T l A a standard was prepared from detergent lysates of 
ACI spleens by MHC class I affinity chromatography as described by 
DeVito et al. (23), except that Sepharose 4B (Sigma, St. Louis, MO) 
coupled to OX-18 and RTlAa-specific mAb 211-4D9 (hybridoma pro-
vided by Heinz Kunz, University of Pittsburgh, Pittsburgh, PA) was used 
as the final affinity column matrix. Test samples or affinity-purified 
RT1 A a Ag were titered in the wells, and incubated 4 to 12 h at 4°C After 
washing, a 1/20 dilution of R3/13 or isotype-control antibody was added, 
and incubated 1 h at room temperature. The plate was washed, and a 
1/200 dilution of mouse anti-rat IgG2b-biotin (Bioproducts for Science) 
was added. After a 1-h incubation at room temperature the plate was 
washed, and a 1/5000 dilution of streptavidin horseradish peroxidase 
(Sigma) was added for 30 min at room temperature. The plate was 
washed, and o-phenylenediamine was added to allow enzymatic conver-
sion of the substrate to a chromogenic product measured at 490 nm (Bio-
tek microplate autoreader, Bio-tek Instruments, Burlington, VT). R T l A a 
concentration was quantitated by linear regression analysis using Bio-tek 
FIGURE 1. Plasmid maps for A) 
pcRT.45 (encoding membrane-bound 
RT1 A a ) , and B) pcRQ.B3 (encoding se-
creted RT1 A a ) are shown, as described 
in Materials and Methods. The RT1 A a 
{cross-hatched)^ 0 b {solid) junction 
created by rPCR is shown, as is the ap-
proximate location of the first stop 
codon in the open reading frame. I, 
leader sequence; TM, transmembrane; 
UT, 3' untranslated region. 
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software, and the purified R T l A a standard. This assay was found to be 
sensitive to 0.5 ng/ml of RT1 A a for tissue culture supernatants and cell 
lysates. The assay was less sensitive (15 ng/ml) when testing for R T l A a 
in serum because of higher background OD readings. 
In vivo gene transfer and cardiac transplantation 
In vivo gene transfer was performed by direct muscle injection of the 
quadriceps muscle, as described previously (10). Heterotopic cardiac 
transplants were performed using a modification of the technique origi-
nally described by Ono and Lindsey (24). Donor hearts were grafted in 
the recipient rat's abdomen by anastomosing donor and recipient aorta, 
and donor pulmonary artery to the recipient's inferior vena cava. Grafts 
were palpated to assess rejection, and nonpalpable contractions prompted 
examination by direct inspection by laparotomy. Graft rejection time was 
defined as the time at which no cardiac contractions were either palpable 
or visible by direct inspection at laparotomy. Grafts were checked twice 
daily and time to rejection was measured from the day of transplant to the 
day of rejection in whole day increments. 
Histochemistry 
Morphologic changes in transplanted hearts were evaluated by staining 
paraffin sections with Mayer's hematoxylin and eosin. For mononuclear 
cell enumeration, stained sections were viewed with a video camera at-
tached to a microscope, and images were processed with the microcom-
puter-based image analysis system, Image-1 (Universal Imaging Corpo-
ration, West Chester, PA). Fifteen areas from multiple sections of the 
myocardium were randomly selected and digitized for each heart al-
lograft. To determine the amount of mononuclear cell infiltration, the 
number of dark staining nuclei per area was determined using the mea-
sure object function of the software after user input of the threshold 
object pixel value. The mean number ± SD of mononuclear cells per 15 
areas was reported. 
The quadriceps muscle was removed and frozen for immunohis-
tochemical examination at the time of rejection of the transplanted heart. 
Immunofluorescent staining was performed on 6 jutm cryostat sections of 
rat skeletal muscle fixed with 2% paraformaldehyde. After washing with 
PBS + 0.05% Tween 20, sections were incubated overnight at 4°C with 
R2-15S rat anti-RTlAa mAb (Bioproducts for Science). After washing in 
PBS and incubating with PBS + 0.05% Tween 20 + 3% goat serum, 
slides were incubated with biotinylated mouse anti-rat IgG2a (Bioprod-
ucts for Science) for 2 h at room temperature. After rinsing with PBS, 
streptavidin-Texas Red conjugate was added. Control sections were 
stained with IgG2a rat anti-RTl A u mAb (Bioproducts for Science) as the 
primary antibody. 
RIA for MHC class l-specific alloantibodies 
Anti-ACI class I IgM and IgG antibody levels were measured using a 
modification of the method reported by Morris and Williams (25). 
Briefly, rat serum was diluted 1/10 in PBS/BSA, and 25 JULI were added 
to duplicate 12 X 75 mm polystyrene tubes. ACI and Lewis (control) 
strain blood was collected in heparinized tubes, washed two times with 
PBS/BSA, and RBC were diluted to 10% (v/v). PVG (control-
RT1A CB CD CC C) and PVG.R1 (RTlA a B c D c C c ) RBC were used in some 
experiments. Diluted cells were added to each tube in 25-jnl aliquots, and 
the serum/cell mixture was incubated for 1 h at room temperature. Cells 
were washed two times with PBS/BSA, resuspended in 100 jxl of PBS/ 
BSA, and incubated 1 h with either 125I-labeled goat anti-rat IgM or 
I25I-labeled goat anti-rat IgG (antibodies purchased from Jackson Immu-
noResearch) antibody at 300,000 cpm/tube. Antibodies were radiolabeled 
with [1 2 5I]Na (Amersham, Arlington Heights, IL) using the IODO-GEN 
iodinating reagent as specified by the manufacturer (Pierce, Rockford, 
IL). After incubation, cells were washed as described above, resuspended 
in PBS/BSA, transferred to fresh tubes, and cpm was determined. Sta-
tistical differences in cpm between experimental and control groups were 
determined by a two-tailed /-test comparing independent sample means. 
Limiting dilution analysis 
Limiting dilution analysis for CTL precursor frequency was performed as 
described in detail previously (26). Twelve replicate cultures «f re-
sponder cells at six dilutions were used in the assay. Target cells were 
either Con A-stimulated ACI or Wistar-Furth (RT1 "-third party) spleno-
cytes. The CTL precursor frequency was calculated using the maximum 
likelihood method as outlined by Deny and Miller (27). 
Results 
To determine if the plasmid constructs encoding mem-
brane-bound and secreted RT1 A a (Fig. 1) were functional, 
mouse L-M(TK) cells were transfected with either 
pcRT.45 or pcRQ.B3 in a transient assay. Figure 2 shows 
an example of one of three experiments with different 
preparations of plasmids. The flow cytometry analysis in-
dicated that pcRT.45, but not pcRQ.BS cDNA-transfer, 
results in cell-surface expression of R T l A a 3 days post-
transfection. Approximately 25% of the pcRT.45-trans-
fected cells expressed the cDNA product at a broad range 
of intensities. Culture supernatants from the same trans-
fections were analyzed for secreted R T l A a by an ELISA. 
Secreted R T l A a was not detected in the culture superna-
tants from the transfection performed with pcRT.45 plas-
mid. However, transfection of the pcRQ.B3 plasmid re-
sulted in 6 ng/ml of R T l A a in the culture supernatant (the 
mean ± SD in three separate experiments was 6 ± 3 
ng/ml). Because transfection efficiency was approximately 
25% and the total number of cells plated was 1 X 106 in 
1.5 ml of culture medium, the total amount of secreted 
R T l A a measured was 9 ng/2.5 X 105 cells. To more 
closely simulate M H C class I expression in donor skeletal 
muscle, total R T l A a production was assessed in primary 
cultured Lewis myoblasts transfected with pcRT.45 or 
pcRQ.B3 (Table I). Cell lysates and culture supernatants 
F l u o r e s c e n c e 
FIGURE 2. Cell-surface expression of RT1A 3 on mouse 
L-M(TK) fibroblast cells after transient transfection with 
pcRQ.B3 {upper) and pcRT.45 {middle), compared with cells 
transfected without addition of plasmid {lower). Results from 
one representative experiment are shown. With pcRT.45 
transfection, 2 7 % of the cells were positive for surface RT1 A a 
by FACS; RT1 A a-positive cells were not detectable with 
pcRQ.B3 transfection. The inset in each histogram shows the 
amount of secreted RT1 A a detected by ELISA in the culture 
supernatant from the same transfection. 
were measured over a 3-day period for RT1 A a by ELISA. 
The pcRT.45-transfected myoblast cell lysates and 
pcRQ.B3-transfected cell culture supernatants showed 
similar amounts of RT1 A a at 48 and 72 h. Secreted RT1 A a 
was not detectable in culture supernatants from pcRT.45-
transfected cells at any of the time points tested. Cell ly-
sates from pcRQ.B3-transfected cells demonstrated no de-
tectable RT1 A a at 24 or 48 h post-transfection, but 2 ng of 
R T l A a was present in the lysate at 72 h. 
Expression of R T l A a was examined 7 days after injec-
tion of pcRT.45. Immunofluorescent staining with mAb 
specific for R T l A a demonstrated that Lewis muscle cells 
at the injection site expressed RT1 A a Ag on their cell sur-
face (Fig. 3A). Muscle cells distant from the injection site 
did not express R T l A a protein. This pattern of myocyte 
expression of transfected plasmid D N A is similar to that 
previously reported for the reporter gene Lac Z (12). As a 
Table I. Total RT1A* produced by pcRT.45 and pcRQ.B3-
transfected Lewis myoblasts3 
Plasmid 
Culture 
Period 
(h) 
Lysate 
(ng/2 X 10 
Supernatant 
5 cells) 
pcRT.45 24 4 <0.56 
48 7 <0.5 
72 17 <0.5 
pcRQ.B3 24 <0.5 <0.5 
48 <0.5 13 
72 2 23 
3 Results are representative of one of two experiments performed, and val-
ues shown are the mean of duplicate determinations. Lysates and culture su-
pernatants from myoblasts transfected with pCMVLux did not show OD read-
ings above control at any of the time points tested. 
b Below the sensitivity of the assay. 
A 
B 
FIGURE 3. A, immunofluorescent staining of pcRT.45-in-
jected rat quadriceps muscle shown here in transverse cross-
section shows RT1A a expression on the cell membrane of 
transfected myocytes (X500). B, transverse section of 
pcRT.45-injected Lewis rat quadriceps muscle stained with 
mAb specific for RT1 A u shows only background fluorescence 
in contrast to A. 
control, the adjacent section was stained with an isotype-
matched mAb specific for RT1A U , and only background 
fluorescence was detected (Fig. 3B). Lewis muscle in-
jected with pCMVLux also did not stain with either anti-
R T l A a or anti-RT!A u mAb (data not shown). 
Table II. Survival of heterotopic cardiac allografts after cDNA 
transfer 
Graft Survival 
Donor Plasmid Dose (days) p Value3 
ACI None 6,6,6,6,6,7 control 
ACI pcRT.45 1,000 fig 3,4,4,4,4,4 <0.001 
600 fig 4,4 
400 fig 4,4 
300 fig 4,5 
100 fig 5,5 
50 fig 4,4 <0.001 
25 fig 4,5,5,6 
10 fig 4,5,5 
5 fig 5,5,5 
1 M<g 5,5,6 
500 ng 6,6 
100 ng 6,7 NS 
ACI pcRQ.B3 1,000 ju-g 5,5,5,5,5b 
600 /xg 5,5,6 0.003 
400 futg 5,5,6 
200 fig 6 
ACI pCMVLux 1,000 fig 6,6,6,6,6 
600 fig .6,6 NS 
W F None 6,6,6,7,7,8,9,9 control 
W F pcRT.45 1,000 fig 7,8,8,9,9 
600 /xg 6,7,9 
400 fig 6,9 
200 fig 7,9 NS 
100 fig 8 
50 fig 7,7 
a Vs control with the same donor (Mann-Whitney test). 
b P < 0.001 when compared with the 1000-fxg dose of pcRT.45. 
One week after pcRT.45 plasmid transfer, an A C I heart 
was transplanted to the Lewis rat recipient. Cardiac trans-
plants rather than skin or other tissues were used to mea-
sure the in vivo alloresponse because the time to rejection 
can be more objectively evaluated by monitoring the pres-
ence or absence of myocardial contraction by direct visual 
inspection. Table II summarizes the graft survival time of 
ACI to Lewis heterotopic cardiac allografts (complete M H C 
and non-MHC mismatch).'Without D N A transfer, ACI hearts 
were consistently rejected at 6 days. Injection of as little as 1 
fxg of pcRT.45 resulted in accelerated rejection, and recipi-
ents receiving injection of 400 /xg or more of pcRT.45 re-
jected at 4 days or less. The degree of the sensitization cor-
related with the dose of pcRT.45 administered. 
To determine whether sensitization was specific for 
RT1 A a , Wistar-Furth (third party) hearts were transplanted 
to Lewis recipients after pcRT.45 injection (Table II). 
There was no alteration of graft survival with any dose of 
D N A administered compared with noninjected controls. In 
addition, injection of 600 to 1,000 /mg of a control plasmid 
encoding firefly luciferase (pCMVLux) did not alter A O -
heart graft survival, although this protein is well expressed 
after direct injection into rodent myocytes (10, 11). 
FIGURE 4. Micrographs of Mayer's hematoxylin-eosin 
stained heart allografts 3 days post-transplantation from 
pCMVLux (A), pcRT.45 (B), and pcRQ.B3 (Q, -injected rats 
(X400). 
Skeletal muscle injection of 1 mg of plasmid encoding 
secreted R T l A a (pcRQ.B3) 1 wk before heart transplan-
tation accelerated rejection slightly, but consistently, from 
6 to 5 days (Table II). A similar degree of acceleration was 
observed with a 200-fold lower dose of pcRT.45 (5 /xg). 
Histologically, hearts from pcRQ.B3-injected rats showed 
a lesser degree of mononuclear cell infiltrate on day 3 
post-transplant, compared with pcRT.45-injected rats (Fig. 
4). Image-1 analysis of cardiac allografts on day 3 post-
transplant confirmed a denser mononuclear cell infiltrate 
in hearts transplanted to pcRT.45-primed recipients com-
pared with pcRQ.B3-injected recipients (6,500 ± 2,683 vs 
1,567 ± 900 per 1 mm 2, respectively), and even less infil-
trate in pCMVLux-injected controls (110 ± 75 per 1 mm2). 
Regardless of the plasmid injected, all hearts showed tissue 
necrosis and a mononuclear cell infiltration typical of acute 
rejection at the time of rejection (data not shown). 
To determine if specific priming of the humoral re-
sponse to R T l A a had occurred by gene transfer, the spe-
cific antibody response was measured using a RIA. Figure 
5 summarizes data from two experiments in which ACI-
specific IgG and IgM antibody levels were determined af-
ter pcRT.45, pcRQ.B3, or pCMVLux injection and sub-
sequent ACI cardiac transplantation. Seven days after 
injection, but before heart transplantation, a 1 -mg dose of 
pcRT.45 did not result in an allospecific IgM or IgG an-
tibody response. Sera were also collected 3 days post-
transplantation to determine whether priming of the anti-
body response to R T l A a had been induced by gene 
transfer. When compared with the weak post-allograft 
anti-ACI IgM antibody response demonstrated by rats in-
jected with pCMVLux control plasmid, the ACI-specific 
IgM antibody levels were consistently higher in rats pre-
treated with a 1-mg dose of pcRT.45. Although pcRQ.B3 
injections elicited an ACI-specific IgM response in some 
animals, the response was found to be more variable. Ac-
celeration of the post-allograft IgG antibody response also 
occurred after pcRT.45 or pcRQ.B3 injection, compared 
with rats injected with control plasmid. As with the IgM 
response, a more variable antibody (IgG) response was 
observed in both experiments after pcRQ.B3 gene transfer. 
More specifically, three out of six animals tested showed 
anti-RTlA a IgM and IgG antibody levels equal to, or 
greater than, the levels observed with pcRT.45 injection; 
the other three rats showed either relatively weak antibody 
responses, or antibody responses similar to control plas-
mid injected rats. The same rats that demonstrated a rel-
atively high IgM antibody response, also showed a high 
IgG antibody response. The presence of RTlA a-specific 
antibodies in the experiments described above was con-
firmed in a separate experiment; antibodies were found 
to bind PVG.R1 ( R T l A a B c D c C c ) R B C , but not P V G 
(RT1A C B C D C C C ) RBC (data not shown). 
C T L frequency determinations were performed to eval-
uate the response of CTL precursors to M H C class I cDNA-
transfer (Table III). Spleens were obtained from plasmid-in-
jected rats on day 3 post-transplant, and tested for frequency 
of ACI-specific CTL. Compared with control plasmid-in-
jected rats, pcRT.45-injected rats showed a marked increase 
in frequency of CTL, suggesting priming by the cDNA-trans-
fer. In contrast, the frequency of ACI-specific C T L was not 
significantly altered by pcRQ.B3 injection. 
Discussion 
Direct gene transfer to skeletal muscle in vivo permits the 
expression of a single foreign protein without potential 
impurities in the Ag or cell preparation caused by imperfect 
protein isolation techniques. The application of this technique 
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FIGURE 5. The effect of gene transfer on ACI-specific antibody production was tested by a RIA. Serum RBC-binding IgM and 
IgG antibody levels were measured: 1) 7 days after gene transfer to Lewis rats, but before A G cardiac transplant, vs ACI RBC 
(open bars); 2) 3 days after ACI cardiac transplants vs ACI RBC {closed bars); or 3) 3 days after ACI cardiac transplants vs control 
Lewis RBC {cross-hatched bars). The graphs at the top represent data from each of two separate experiments where ant i -AG 
IgM antibody levels were measured; the bottom graphs are data from two separate experiments where anti-AG IgG antibody 
levels were measured. Results represent the mean ± SD of pooled data from multiple rats. Statistical comparisons are relative 
to pCMVLux controls at the same time point (f-test). 
Table III. Effect of gene transfer on the frequency of ACI-specific 
CTL 
1/Frequency 
Wistar-Furth 
Plasmid 
targets 
No. ACI targets (third party) 
pCMVLux (control) 3 3,476 ± 1,442 10,322 ± 999 
pcRT.45 3 1,077 ± 378a 10,056 ± 5,902 
pcRQ.B3 3 2,135 ± 452 9,484 ± 2,756 
3 p < 0.05 compared with control (f-test). 
to transplantation offers the possibility of measuring the im-
pact of constitutively expressed, genetically engineered, 
M H C proteins on graft rejection or prolongation. Expression 
by a nonmobile cell offers the analogy with a long term 4'pas-
senger cell"-depleted graft, and precludes the element of re-
circulation of alloantigen-bearing cells. 
Experiments presented in this study demonstrate that 
M H C cDNA transfer in vivo results in expression of 
allogeneic class I A g by myocytes. Membrane-bound 
R T l A a was demonstrated by immunohistochemistry in 
pcRT.45-injected skeletal muscle 7 days postinjection. Se-
creted RT1 A a , after pcRQ.B3 injection at the doses used in 
these experiments, was not detected in serum using an 
ELISA sensitive to 15 ng/ml (data not shown). However, 
indirect evidence for expression of the protein was indi-
cated by: 1) priming of the humoral response to R T l A a , 
and 2) consistent 1-day acceleration of A C I heart allograft 
rejection (1-mg dose). The membrane-bound or secreted 
nature of the M H C class I Ag produced as a result of 
transfecting either pcRT.45 or pcRQ.B3 was confirmed in 
vitro. Transfection of cells with pcRT.45 resulted in the 
production of R T l A a that was detectable in association 
with the cell membrane, but not detectable as a secreted 
molecule. In contrast, pcRQ.B3-transfection resulted in 
the production of secreted, but not membrane-bound, 
R T l A a . It is noteworthy that a small amount of R T l A a 
was detectable in cell lysates of pcRQ.B3-transfected 
cells. This result most likely represented intracellular mol-
ecules that had not been exported to the cell surface, be-
cause RT1 A a molecules were not detectable on the surface 
of pcRQ.B3-transfected cells by FACS analysis. 
Direct muscle injection of c D N A encoding either mem-
brane-bound or secreted M H C class I Ag changed the k i -
netics of heart allograft survival, as well as the antibody 
response. Injection of pcRT.45 resulted in acceleration of 
allograft rejection by >2 days, while pcRQ.B3 injection 
resulted in only a 1-day acceleration of graft rejection. 
Lower priming by pcRQ.B3 compared with pcRT.45 in-
jection suggests that either secreted R T l A a encoded by 
pcRQ.B3 is less immunogenic, or pcRQ.B3 is not well 
expressed by muscle cells. However, our in vitro results 
showing that similar levels of R T l A a are produced by 
myoblasts transfected with either pcRQ.B3 or pcRT.45 
tend to exclude the trivial explanation of our in vivo re-
sults being caused by a large difference in gene expression 
between the two plasmids. Interestingly, the humoral re-
sponse was consistently primed by pcRT.45 injection, but 
priming was less consistent in pcRQ.B3-injected animals. 
In some rats pcRQ.B3 injection induced an accelerated 
antibody response equal to, or greater than, pcRT.£)-in-
jected animals. In others, the priming was weak, or not 
discernible from controls. It is possible that the differing 
immunologic responses to membrane-bound and secreted 
R T l A a , or the variability observed with pcRQ.B3 injec-
tion was caused by a local concentration effect in vivo. 
Secreted R T l A a could be rapidly removed from the local 
environment, depending on local vascularization, whereas 
membrane-bound R T l A a would likely remain at a rela-
tively high local concentration as a result of association 
with nonmobile cells. 
The immunologic response to M H C class I Ag depends 
on the direct and indirect pathway of alloantigen presen-
tation to T cells. With the direct pathway of Ag presenta-
tion in organ transplantation, recipient T cells respond di-
rectly to intact M H C class I molecules on the surface of 
allogeneic cells. T cells that recognize these molecules 
have a high frequency, and are a major factor mediating 
early allograft rejection (28-31). With the indirect path-
way allogeneic M H C class I Ag is recognized in the form 
of polymorphic peptides presented in association with re-
cipient M H C class II molecules (32). This is a pathway by 
which Th cells recognize allogeneic M H C class I Ag. A l -
though Ag-activated Th cells secrete cytokines that induce 
proliferation and differentiation of antibody-producing B 
cells, the contribution of indirect Ag presentation to the graft 
rejection process is poorly understood. Based on the ability of 
pcRQ.B3 injection to prime the antibody response to RT1 A a , 
our data supports a potential role for the indirect pathway of 
M H C class I Ag presentation in mediating graft rejection. It 
is likely that the indirect pathway of Ag presentation was 
used with pcRQ.B3 injection, because RT1 A a molecules en-
coded by the plasmid were secreted and not retained by the 
cell membrane, as demonstrated by ELISA and FACS anal-
ysis, respectively. In support of this theory, we have recently 
found that high doses of water-soluble recombinant human/ 
mouse fusion proteins HLA-A2/Q10 b and HLA-B7/Q10 b 
stimulate BL-2 production by C D 4 + human T cells via an 
indirect pathway (33). It has also been reported previously 
that monovalent M H C class I molecules (H-2D d) genetically 
engineered into secreted proteins using the mouse Q10b-re-
gion do not stimulate CD8 + , H-2Dd-specific, T cells in vitro 
unless they are rendered polyvalent (34). Because pcRT.45 
injection primed the C T L and antibody response against do-
nor tissue, and accelerated allograft rejection, one interpreta-
tion of our results would be that polyvalent, membrane-
bound, M H C class I leads to more efficient allosensitization 
by utilizing both pathways of Ag presentation. Transfected 
myocytes that express membrane-bound R T l A a could di-
rectly stimulate host CTL, and the membrane-bound form, 
shed by the myocytes, could be processed and presented by 
host APC to recipient Th cells via the indirect pathway of Ag 
presentation. 
Interestingly, pcRT.45 and pcRQ.B3 plasmid injections 
had a different effect on the CTL response. Injections of 
pcRQ.B3 did not appreciably prime the C T L response to car-
diac allografts, whereas pcRT.45 injection did prime CTL. 
Although myocytes are not known to possess costimulator 
activity, the greater C T L response and greater acceleration of 
graft rejection caused by pcRT.45 compared with pcRQ.B3 
injection suggests that some form of the direct pathway (i.e., 
stimulation of C T L by myocyte-expressed membrane-bound 
R T l A a ) may operate in effecting sensitization. A study by 
Rogers and Mescher (35), which shows C T L can be primed 
without costimulation using cell-sized particles coated with 
M H C class I Ag, suggests myocyte costimulatory activity 
may not be necessary for C T L priming. 
Our findings indicate that acceleration of graft rejection 
was not directly correlated with levels of specific antibody 
because pcRQ.B3-injected rats consistently rejected al-
lografts only 1 day early despite variable antibody priming. 
Thus, for example, a rat with a high IgG anti-ACI antibody 
response on day 3 rejected no faster than one with a low IgG 
antibody response. These results agree with previous studies 
in which cytotoxic antibody levels were not found to corre-
late with cardiac allograft rejection time (36, 37). Fangmann 
et al. (32) described the ability of the indirect pathway of 
allorecognition to sensitize high-responder strain Lewis rats. 
This group used two immunizations with C F A in combina-
tion with RTlA a v l-derived peptides to achieve accelerated 
rejection of a skin allograft and a secondary antibody re-
sponse to R T l A a v l . Because C F A is lipophilic, this protocol 
may be more analogous to our use of cDNA encoding mem-
brane-bound R T l A a , which is also lipophilic. 
In summary, results from this study support the premise 
that membrane-bound and secreted M H C class I A g have 
different immunogenic properties in vivo, and show that 
direct gene transfer to skeletal muscle is an effective 
means by which alloimmunity to specific M H C proteins 
can be examined. 
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